Double-blind, parallel-group, placebo-controlled study to compare a four week continuous ingestion effect of Champignon extract on fecal odor, body odor, oral odor and enteric environment of the subjects.

Double-blind, parallel-group, placebo-controlled study to compare a four week continuous ingestion effect of Champignon extract on fecal odor, body odor, oral odor and enteric environment of the subjects. - Effects of Champignon extract on fecal odor, body odor, oral odor and enteric environment of the subjects.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014256

Enrollment

Registered

2014-06-16

Start date

2014-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fecal odor, body odor, oral odor

Interventions

Two grams of powder containing 50mg of Champignon extract, ingested daily over a period of four weeks. Two grams of powder containing 200mg of Champignon extract, ingested daily over a period of four

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Subjects who are worried about fecal odor, body odor or oral odor 2.A subject with an observer, for objectively evaluating above odors.

Exclusion criteria

Exclusion criteria: 1.Subjects who are suffering from serious cerebrovascular disease, heart disease, liver disease, renal disease, gastrointestinal disease or any infectious disease which needs immediate reporting. 2.Subjects with a clinical history of gastrointestinal cancer or are currently under its medical treatment. 3.Subjects having a clinical history of gastrectomy, gastrointestinal suture, bowel resection or any major surgery in the digestive system. 4.Subjects having a gastrointestinal disorder, irritable bowel syndrome, inflammatory bowel syndrome etc. 5.Subjects under the medication for bowel movements (such as antibiotics, laxatives, medicine for constipation) or using functional foods and supplements (containing lactic acid bacteria, bifidobacterium, oligosaccharides, dietary fiber etc.) 6.Subjects who will undergo dental treatment during this study period. 7.Subjects with frequent complaints of post-menopausal symptoms. 8.Subjects with unusually high and/or low blood pressure, or with abnormal hematological data. 9.Subjects with serious anemia. 10.Subjects with a history of allergy to medicine and food (especially mushroom). 11.Subjects who have defecation frequency less than four times per week or those who suffer from diarrhea. 12.Subjects who are heavy smokers or alcoholics, or exhibit irregular pattern in their lifestyles such as meals or sleep etc. 13.Subject who has donated 400ml whole blood within past 12 weeks or 200ml within past 4 weeks or who has donated plasma or platelets within past 2 weeks prior to this study. 14.Subjects who are pregnant or under lactation, or who expect to get pregnant during this study period. 15.Subject who has participated in other clinical trials within past one month or is currently undergoing any clinical trial. 16.Subjects who are judged ineligible by our physician.

Design outcomes

Primary

Measure	Time frame
Fecal analysis (odor component, intestinal bacterial flora), fecal diary, VAS questionnaire for body odor, oral odor and bowel movement.	—

Secondary

Measure	Time frame
Natural killer cell activity	—

Countries

Japan

Contacts

Public ContactDir. Prof. Jun Nishihira, M.D.

Hokkaido Information University Health Information Science Center

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026